Chronic kidney disease (CKD) affects up to 26 million Americans, or 13% of the United States population. Moderate-severe CKD (stage 3-4, defined by glomerular filtration rate 15-59 mL/min/1.73m2) has a particularly large public health impact because it is most prevalent and because it potently amplifies risk of cardiovascular disease. Specifically, individuals with moderate-severe CKD have important "non-traditional" risk factors for cardiovascular disease which are not adequately addressed by risk reduction strategies developed for the general population. Insulin resistance is one "non-traditional" mechanism through which CKD may cause cardiovascular disease. In CKD, post-receptor resistance to insulin action in skeletal muscle is commonly acquired due to unique metabolic abnormalities, including impaired renal calcitriol synthesis, metabolic acidosis, and accumulation of uremic toxins. In turn, insulin resistance may promote cardiovascular disease by impairing endothelial function, increasing reactive oxygen species, and exacerbating systemic inflammation. The metabolic abnormalities unique to CKD fundamentally alter the pathophysiology and ascertainment of insulin resistance and offer novel potential targets for therapeutic intervention. The overall goal of this grant application is to comprehensively characterize insulin resistance in moderate- severe CKD. First, we propose to define the severity of insulin resistance, the compensatory response of the pancreatic beta cell, and net effects on glucose tolerance, which are currently poorly understood, using gold standard methods (hyperinsulinemic euglycemic clamp, intravenous glucose tolerance test, oral glucose tolerance test). Second, we propose to develop and validate formulae estimating insulin resistance for use in future epidemiologic studies and clinical trials. Third, we propose to test associations of insulin resistance with endothelial function, oxidative stress, and inflammation. To accomplish these goals, we have assembled a multidisciplinary team with expertise in the biology of CKD, metabolism, quantitative assessment of insulin sensitivity and beta-cell function, nutrition, and biostatistics. As part of this innovative collaborative approach, this study will take advantage of existing resources at the University of Washington and the Kidney Research Institute in Seattle. These include the Institute for Translational Health Sciences Clinical Research Center, Nutrition and Body Composition Core, and Center for Biomedical Statistics.

Public Health Relevance

Moderate-severe CKD is an important public health problem due to its high prevalence and poor health outcomes. The key to improving long-term health outcomes in this population is prevention of cardiovascular disease. Persons with stage moderate-severe CKD are at high risk of cardiovascular events and are up to 11 times more likely to die, mostly due to cardiovascular disease, than to progress to kidney failure. Once completed, the proposed studies will provide a sound empirical basis to support the design of future large epidemiologic studies and clinical trials targeting insulin resistance in CKD. The ultimate goal of this work is to reduce the high morbidity and mortality in the large group of patients with moderate-severe CKD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK087726-03
Application #
8318886
Study Section
Kidney, Nutrition, Obesity and Diabetes (KNOD)
Program Officer
Flessner, Michael Francis
Project Start
2010-08-15
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
3
Fiscal Year
2012
Total Cost
$480,744
Indirect Cost
$172,575
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
de Boer, Ian H; Sachs, Michael C; Chonchol, Michel et al. (2014) Estimated GFR and circulating 24,25-dihydroxyvitamin D3 concentration: a participant-level analysis of 5 cohort studies and clinical trials. Am J Kidney Dis 64:187-97
de Boer, Ian H; Mehrotra, Rajnish (2014) Insulin resistance in chronic kidney disease: a step closer to effective evaluation and treatment. Kidney Int 86:243-5
DCCT/EDIC research group (2014) Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2:793-800
de Boer, Ian H; Brunzell, John D (2014) HDL in CKD: how good is the "good cholesterol?". J Am Soc Nephrol 25:871-4
de Boer, Ian H; Sun, Wanjie; Cleary, Patricia A et al. (2014) Longitudinal changes in estimated and measured GFR in type 1 diabetes. J Am Soc Nephrol 25:810-8
de Boer, Ian H; DCCT/EDIC Research Group (2014) Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37:24-30
Sachs, Michael C; Brunzell, John D; Cleary, Patricia A et al. (2013) Circulating vitamin D metabolites and subclinical atherosclerosis in type 1 diabetes. Diabetes Care 36:2423-9
de Boer, Ian H; Sachs, Michael; Hoofnagle, Andrew N et al. (2013) Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease. Kidney Int 83:323-30
Afkarian, Maryam; Sachs, Michael C; Kestenbaum, Bryan et al. (2013) Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24:302-8
de Boer, Ian H; Kestenbaum, Bryan (2013) Invited commentary: Quantifying salt in urine--a complex solution. Am J Epidemiol 177:1193-5; discussion 1196-8

Showing the most recent 10 out of 18 publications